1. Cholewinksi, SP, Yoo, KS, Klieger, PS, O' Mara, RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med. 1991;41:1198-1202.
Google Scholar2. Dinneen, SF, Valimaki, MJ, Bergstralh, EJ, Goellner, JR, Gorman, CA, Hay, ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metabol. 1995;80(7):2041-2045.
Google Scholar | Medline3. Casara, D, Rubello, D, Saladini, G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med : official publication, Society of Nuclear Medicine. 1993;34(10):1626-1631.
Google Scholar | Medline4. Mazzaferri, EL, Kloos, RT. current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metabol. 2001;86(4):1447-1463.
Google Scholar | Crossref | Medline | ISI5. Eustatia-Rutten, CFA, Corssmit, EPM, Biermasz, NR, Pereira, AM, Romijn, JA, Smit, JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metabol. 2006;91(1):313-319.
Google Scholar | Crossref | Medline6. Aboelnaga, EM, Ahmed, RA. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. Cancer biology & medicine. 2015;12:53-59.
Google Scholar | Medline7. Regalbuto, C, Malandrino, P, Tumminia, A, Le Moli, R, Vigneri, R, Pezzino, V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21:383-389.
Google Scholar | Crossref | Medline8. Silver, CE, Owen, RP, Rodrigo, JP, Rinaldo, A, Devaney, KO, Ferlito, A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011;33:1052-1059.
Google Scholar | Crossref | Medline | ISI9. Hundahl, SA, Fleming, ID, Fremgen, AM, Menck, HR A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S.,1985-1995. Cancer. 1998;83:2638-2648.
Google Scholar | Crossref | Medline | ISI10. Burns, WR, Zeiger, MA. Differentiated thyroid cancer. Semin Oncol. 2010;37(6):557-566.
Google Scholar | Crossref | Medline11. Mirghani, H, Altidlawi, MI, Altedlawi Albalawi, IA. The optimal activity of radioactive iodine for remnant ablation in low/intermediate risk differentiated thyroid carcinoma: a continuous controversy and meta-analysis. Cureus. 2021;13(1):12937.
Google Scholar12. Vardarli, I, Weidemann, F, Aboukoura, M, Herrmann, K, Binse, I, Görges, R. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid cancer in low and intermediate risk patients: a meta-analysis. BMC Cancer. 2020;20:550.
Google Scholar | Crossref | Medline13. Masood, K, Masood, A, Zafar, J, et al. Trends and Analysis of Cancer Incidence for Common Male and Female Cancers in the Population of Punjab Province of Pakistan during 1984 to 2014. Asian Pac J Cancer Prev: Asian Pacific Organization for Cancer Prevention 2015;16:5297-304.
Google Scholar | Crossref | Medline14. Drozd, V, Saenko, V, Branovan, DI, Brown, K, Yamashita, S, Reiners, C. A search for causes of rising incidence of differentiated thyroid cancer in children and adolescents after chernobyl and fukushima: comparison of the clinical features and their relevance for treatment and prognosis. Int J Environ Res Publ Health. 2021;18(7):3444.
Google Scholar | Crossref | Medline15. Lv, R-B, Wang, Q-G, Liu, C, et al. Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer. OncoTargets Ther. 2017;10:4051-4057.
Google Scholar | Crossref | Medline16. Ibrahim, DR, Kelany, MR, Michael, MM, Elsayed, ZM. Low-dose versus high dose radioactive iodine ablation differentiated thyroid carcinoma: a prospective randomized study. J Clin Oncol. 2016;34(15):6087.
Google Scholar | Crossref17. Fatima, N, Zaman, Mu., Zaman, A, Zaman, U, Tahseen, R. Comparable ablation efficiency of 30 and 100 mci of i-131 for low to intermediate risk thyroid cancers using triple negative criteria. Asian Pac J Cancer Prev APJCP. 2016;17(3):1115-1118.
Google Scholar | Crossref | Medline18. Hackshaw, A, Harmer, C, Mallick, U, Haq, M, Franklyn, JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metabol. 2007;92(1):28-38.
Google Scholar | Crossref | Medline19. Mallick, U, Harmer, C, Yap, B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674-1685.
Google Scholar | Crossref | Medline20. Schlumberger, M, Catargi, B, Borget, I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663-1673.
Google Scholar | Crossref | Medline21. Cheng, W, Ma, C, Fu, H, et al Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metabol. 2013;98:1353-1360.
Google Scholar | Crossref | Medline22. Lou, K, Gu, Y, Hu, Y, Wang, S, Shi, H. Technetium-99m-pertechnetate whole-body SPET/CT scan in thyroidectomized differentiated thyroid cancer patients is a useful imaging modality in detecting remnant thyroid tissue, nodal and distant metastases before 131I therapy. a study of 416 patients. Hellenic Journal of Nuclear Medicine. 2018;21(2):121-124.
Google Scholar | Medline23. González, C, Aulinas, A, Colom, C, et al. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma. Clin Endocrinol. 2014;80(2):301-306.
Google Scholar | Crossref | Medline24. Perros, P, Boelaert, K, Colley, S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81(1):1-122.
Google Scholar | Crossref | Medline25. Luster, M, Dietlein, SEM, Lassmann, M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imag. 2008;35:1941-1959.
Google Scholar | Crossref | Medline26. Haugen, BR, Alexander, EK, MandelDoherty, SJNYE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 2016;26(1):1-133.
Google Scholar | Crossref | Medline | ISI